Sellas Life Sciences Reports Encouraging Immune Response From GPS Combo Trial In Ovarian Cancer

Sellas Life Sciences Group Inc SLS has announced updated data and initial immunobiological data from its Phase 1/2 evaluating its lead asset, galinpepimut-S (GPS), in ovarian cancer.
Conducted in collaboration with Merck & Co Inc MRK, the study is investigating the combination of GPS and (Keytruda) (pembrolizumab) in patients diagnosed with second- or third-line WT1(+) relapsed or refractory platinum-resistant, advanced metastatic ovarian cancer.
In the cohort of 11 patients, a disease control rate (DCR) of 63.6%, with a median follow-up of 15.4 weeks, was observed.
Median progression-free survival (PFS) was 11.8 weeks. The landmark PFS rate by log-rank analysis at six months (26 weeks) was 33%.
All patients are alive, and five patients (45.5%) are continuing to receive investigational therapy.
Enrollment is ongoing, with a target of approximately 20 total evaluable patients.
Immune Data showed that GPS induced WT1-specific immune responses with a substantial increase in antigen-reactive T-lymphocytes averaging +242% for CD8+ and +80.5% for CD4+ T-cells from baseline to 18 weeks post-treatment.
The safety profile of the GPS-pembrolizumab combination was similar to that seen with pembrolizumab alone, with the addition of only low-grade, temporary local reactions at the GPS injection site.
Price Action: SLS shares are down 8.87% at $11.91 during the market session on the last check Wednesday.

Earnings Calendar